Overview

• The network connects 37 U.S. locations, placing millions of people within roughly 90 minutes of a City of Hope site.
• In the initial rollout, nine trials spanning solid tumors and blood cancers are active at 12 sites with enrollment running ahead of expectations.
• A Phase 2 study of Eli Lilly’s therapy for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma is open at eight locations.
• City of Hope is developing AI and predictive tools to identify eligible patients and select optimal sites for each trial.
• The digitally connected hub-and-spoke design streamlines startup and enrollment to reduce ZIP code–based disparities and enable rapid expansion.